

Elliot Staffin  
Office of International Corporate Finance  
U.S. Securities and Exchange Commissions,  
Station Place Headquarters,  
100 F. St. N.E.,  
Washington, D.C. 20549  
USA

2006 AUG 18 P 2:05

OFFICE OF INTERNATIONAL  
CORPORATE FINANCE

08/09/2006



06016137

SUPPL

Re.: SEC File Number, 82-5116

This information is furnished pursuant to Rule 12g3-2(b).

Kindly receive stock exchange announcements no. 16 of August 2006.

Yours sincerely  
Novozymes A/S

  
Ella Begtrup  
Investor Relations  
+45 44 42 23 79

PROCESSED

AUG 23 2006 *E*

THOMSON  
FINANCIAL



Novozymes A/S  
Investor Relations

Krogshoejvej 36  
2880 Bagsvaerd  
Denmark

Tel.:  
+45 8824 9999  
Fax:  
+45 4442 1002

Internet:  
[www.novozymes.com](http://www.novozymes.com)  
CVR no.:  
10 00 71 27

## Group financial statement for first half of 2006

August 8, 2006

**Novozymes maintains the high earnings level. Growth in sales and operating profit of 8% and 10% respectively for the first half of 2006 is in line with the company's expectations. The full-year outlook for earnings remains unchanged, while the outlook for free cash flow is increased to DKK 850-950 million.**

- Sales rose by 8% to DKK 3,282 million from DKK 3,037 million in the first half of 2005. Measured in local currencies, sales rose by just over 5%
- Operating profit rose by 10% to DKK 657 million from DKK 597 million in 2005
- The operating profit margin for the first half of 2006 was 20.0%, compared with 19.7% in the same period of 2005
- Net financial costs were DKK 66 million against DKK 8 million in 2005
- Profit before tax was DKK 591 million, largely on a par with the first half of 2005
- Net profit for the period was DKK 443 million, marginally higher than the figure of DKK 441 million in 2005. Earnings per share for the period (diluted) were DKK 6.72, an increase of approximately 4%
- Free cash flow before acquisitions rose by 25% to DKK 600 million, compared with DKK 480 million in 2005
- Return on invested capital (ROIC) was 19.7%, the same as last year

### Outlook for 2006

Novozymes maintains its outlook for 2006 as published in January 2006. However, the outlook for free cash flow is being adjusted upwards from DKK 750-850 million to DKK 850-950 million, mainly as a result of tax-related one-off items. Growth in sales is expected to remain at 7-9% in DKK and 6-8% in local currencies. Operating profit is expected to grow at 7-9%, while growth in net profit is expected to be 5-7%.



Unlocking the magic of nature

RECEIVED  
2006 JUN 19 PM 2:07  
OFFICE OF INTERNATIONAL  
CORPORATE RELATIONS

"We are satisfied," says Steen Riisgaard, President and CEO. "With sales growth of 8% in DKK and just above 5% in local currencies, we are in line with our expectations for the period. We have also managed to achieve good productivity improvements in the first half, which underpin our earnings level and enable us to maintain our high operating profit margin at the same time as investing more in long-term growth. In the light of the results for the first half, we are standing by our outlook for the year within the parameters presented to the market in January 2006.

The recently completed acquisition of the UK company, Delta Biotechnology Ltd (now Novozymes Delta Ltd), is part of the company's strategy of developing a platform for ingredients for the biopharmaceutical industry. The existing product portfolio and pipeline from Novozymes Delta Ltd complements our existing projects within this area very well, and further it supports our continued expansion within media for cell cultures."


## Income statement and balance sheet

### Appendix 1


#### Sales

Sales in the first half of 2006 were DKK 3,282 million, an increase of 8% compared with the same period of 2005. Sales were positively affected by exchange rates. Measured in local currencies, sales rose by just above 5%. Activities acquired at the end of 2005 and the beginning of 2006 had a small positive effect on total sales. Organic growth in the first half of 2006 was 5%.

Sales in DKK mill.



Distribution of sales, 1H 2006



Sales rose by 6% in the second quarter of 2006 compared with the second quarter of last year. As a result of exchange rate movements, particularly in the USD, the exchange rate effect was significantly smaller than in the first quarter of 2006. Measured in local currencies, growth in the period was 5%.

### Appendices 1 and 2

#### Sales of enzymes

Sales of enzymes rose by just under 8% to DKK 3,098 million from DKK 2,881 million in the first half of 2005. Exchange rate movements had a positive effect on sales of just over 2 percentage points.

#### Stock exchange announcement no. 16, 2006

Novozymes A/S  
Investor Relations  
2006-38381-01


Krogshøjvej 36  
2880 Bagsvaerd  
Denmark

Telephone:  
+45 8824 9999  
Telefax:  
+45 4442 1002

#### Page 2 of 21


Internet:  
www.novozymes.com  
CVR number:  
10 00 71 27

Sales in DKK million




Sales of **detergent enzymes** rose by 1% in the first half of 2006 compared with the same period of 2005. There was a small positive exchange rate effect in the first half of 2006, with sales measured in local currencies on a par with 2005. The impact of higher detergent ingredient prices on enzyme sales has stabilised and, combined with continued growth in Third World markets, a slightly positive growth is expected for 2006.

There was a small increase in sales in both DKK and local currencies in the second quarter of 2006 compared with the same quarter of 2005.




Sales of **other technical enzymes** rose by 21% compared with the first half of 2005. This figure includes a positive exchange rate effect of approximately 4 percentage points. There was double-digit growth in sales of enzymes for the fuel ethanol and starch industries, while growth in sales of enzymes for the textile industry was lower. Growth in sales of enzymes for fuel ethanol continued to outstrip growth in production of fuel ethanol. Sales of pharmaceutical proteins and hyaluronic acid grew healthily, albeit still from a relatively low level.

The trend in the second quarter of 2006 compared with the second quarter of 2005 reflected the trend for the first half as a whole. In both cases growth was primarily driven by increased sales of enzymes for the fuel ethanol and starch industries.



Sales of **food enzymes** rose by 5% in DKK in the first half of 2006, and by just above 2% in local currencies. The trend in 2006 should be seen in the light of a challenging basis of comparison for the first half of 2005, where some of the growth related to stockbuilding at the distributor level. Growth in the first half of 2006 was primarily driven by progress in sales of baking enzymes and enzymes for alcohol, but sales of enzymes for processed foods also grew healthily.


Seen in isolation, growth in the second quarter of 2006 was also affected by stockbuilding in the same quarter last year. Sales of baking enzymes and enzymes for alcohol contributed most to the overall trend for the period.



Sales of **feed enzymes** rose by 1% in the first half of 2006 compared with 2005. Measured in local currencies, sales were 2% lower than in 2005. The trend in sales was strongly influenced by changes in the stock levels held by Novozymes' partner. Disregarding this impact, penetration of phytase continued in the markets outside Europe. The fluctuating stock levels are expected to level out over the course of 2006, and are therefore not expected to affect the growth outlook for the year.

Sales of feed enzymes rose by 3% in the second quarter of 2006 compared with the second quarter of last year. The increase in local currencies was 2%. The trend in the second quarters of both 2005 and 2006 was characterised by fluctuations in the stock levels held by Novozymes' partner.

Sales in DKK million



Appendix 2

### Sales of microorganisms

Sales of microorganisms rose by 18% in the first half of 2006 compared with the first half of 2005. Adjusted for the positive exchange rate effect, sales rose by 14%. Growth was primarily driven by increased sales for institutional and household cleaning and wastewater treatment. There was a generally positive trend across the business area, with all areas achieving healthy growth. There was also double-digit growth in all geographical areas.

Compared with the same period of 2005, sales in the second quarter of 2006 rose by 10% in both DKK and local currencies. As for the first half as a whole, growth was primarily driven by the positive trend in sales for institutional and household cleaning.

### Sales by geographical area

Sales in Europe in the first half of 2006 were largely on a par with the same period of 2005. The highest growth was achieved in sales of enzymes for fuel ethanol and sales of microorganisms. In the main the positive trend was balanced out by a fall in sales of baking and feed enzymes.

Growth in North America remained high, with sales rising by just below 19%, including a positive exchange rate effect of approximately 6%. The most positive trend was recorded in sales of enzymes for fuel ethanol and for the starch and baking industries. There was also healthy growth in sales of feed enzymes and microorganisms. Growth was reduced in part by lower sales of detergent enzymes.

Sales in Asia rose by 13%. The underlying growth in local currencies was 9%, driven by progress in virtually all industries but particularly in sales to the detergent and starch industries.

Sales in Latin America were 7% higher than in 2005. Adjusted for the positive exchange rate effect, growth in local currencies was 2%. This positive trend was driven primarily by healthy growth within both detergent and feed enzymes.

### New products

Novozymes launched four new products in the first half of 2006, specifically three new enzymes and one new microorganism:

- Liquanase<sup>®</sup>, a detergent enzyme which is effective on protein-based stains, particularly dried-in blood, and gets clothes clean at lower temperatures
- Cerezyme<sup>®</sup>, an enzyme for brewing based on sorghum
- BPX-1, a more effective enzyme for starch based fuel ethanol produced by the one-step process (also known as 'the cold process')

Stock exchange announcement no. 16, 2006

Novozymes A/S  
Investor Relations  
2006-38381-01

Krogshøjvej 36  
2880 Bagsvaerd  
Denmark

Telephone:  
+45 8824 9999  
Telefax:  
+45 4442 1002

Page 4 of 21

Internet:  
[www.novozymes.com](http://www.novozymes.com)  
CVR number:  
10 00 71 27

- Novo BioClean, a microorganism for institutional and household cleaning used to clean carpets

Sales of new products launched in the last five years represented approximately 30% of the Group's sales in the first half of 2006.

## Appendix 1

### Costs, Licence fees and Other operating income

Total costs excluding net financials and tax rose by 8% to DKK 2,647 million from DKK 2,459 million in the first half of 2005.

Production costs rose by just below 7% compared with the first half of 2005, and were negatively affected by higher raw material and energy prices and also by higher exchange rates compared with the same period of 2005. The gross margin rose to 54.7%, against 54.0% last year, mainly due to productivity improvements within production.

Other operating costs rose by 9%. The trend was negatively affected by exchange rates and must also be seen against the background of a relatively low cost level in the first half of 2005. Some of the increase in costs was also related to the strategic initiative concerning market-expanding activities launched in August 2005.

In the first half of 2006 sales and distribution costs represented approximately 12% of sales for the period, while research and development costs and administrative costs represented 13% and 10% respectively.


Other operating income rose by 16% to DKK 22 million in the first half of 2006, compared with DKK 19 million in 2005. This increase was mainly due to a higher level of income from the research collaboration with Solvay Pharmaceuticals.

Depreciation and amortisation charges fell by 11% to DKK 214 million from DKK 240 million in the first half of 2005.


## Appendix 1

### Operating profit

Operating profit (EBIT), DKK million



Operating profit margin, %



Stock exchange announcement no. 16, 2006

Novozymes A/S  
Investor Relations  
2006-38381-01

Krogshøjvej 36  
2880 Bagsvaerd  
Denmark

Telephone:  
+45 8824 9999  
Telefax:  
+45 4442 1002

Page 5 of 21

Internet:  
[www.novozymes.com](http://www.novozymes.com)  
CVR number:  
10 00 71 27

Operating profit rose to DKK 657 million from DKK 597 million, equivalent to an increase of 10%. This figure was positively affected by exchange rate movements. The operating profit margin, expressed as operating profit as a percentage of sales, was 20.0% against 19.7% in 2005.

Appendix 1

**Net financial items**

Net financial costs rose to DKK 66 million from DKK 8 million in the first half of 2005. This increase was mainly due to a net foreign exchange loss of DKK 51 million on hedging the Group's currency exposure, particularly to the USD. Net interest expenses in the first half of 2006 were lower than in 2005 as a result of tax-related non-recurring interest income. Employee share options increased net financial costs by approximately DKK 6 million in the first half of 2006.

Net interest-bearing debt rose to DKK 1,030 million, compared with DKK 788 million in the first half of 2005 and DKK 877 million at year-end 2005.

Appendix 1

**Profit before tax and net profit for the period**

Profit before tax for the first half of 2006 was DKK 591 million, largely on a par with the profit of DKK 589 million for the same period of 2005. Net profit for the period was DKK 443 million, which was marginally higher than the corresponding figure of DKK 441 million in 2005. The main factor in the trend in net profit was higher net financial costs in the first half of 2006. The outlook for growth in net profit remains unchanged at 5-7%.

Appendix 3

**Cash flow, investments and acquisitions**

Free cash flow before acquisitions rose by 25% to DKK 600 million from DKK 480 million in the corresponding period of 2005. Tax-related non-recurring items had a positive impact on free cash flow in the second quarter of 2006, and were the main factors in the increase.

An increase in working capital, mainly as a result of an increase in inventories and receivables, had a negative impact on cash flow from operating activities. As expected, there was also an increase in net investments before acquisitions from DKK 125 million in 2005 to DKK 184 million in the first half of 2006. This increase was mainly due to the conversion of Novozymes' production facilities in Lund, Sweden.

In January 2006 Novozymes bought a small Chinese company within the biopolymers area. Taking this into account, free cash flow after acquisitions was DKK 534 million. In June Novozymes announced the purchase of Delta Biotechnology Ltd (now Novozymes Delta Ltd). The transaction was completed on July 6, 2006 and is thus not included in the financial statements for the first half of 2006.

**Balance sheet and Statement of shareholders' equity**

Shareholders' equity was DKK 3,509 million at the end of the first half of 2006, compared with DKK 3,794 million on January 1, 2006. Shareholders' equity was increased by net profit for the period but reduced by currency translation adjustments in respect of subsidiaries' net assets, dividend payments and purchase of treasury shares. Shareholders' equity represented 48% of the balance sheet total at June 30, 2006.

A dividend of DKK 257 million was paid for 2005. Purchase of treasury shares (DKK 558 million), reduced by exercise of share options (DKK 90 million), decreased shareholders' equity by DKK 468 million in the period.

The Annual Meeting of Shareholders on March 1, 2006 passed a resolution to write down the nominal share capital by DKK 46 million by means of cancelling part of the company's holding of B shares. The write-down was effected in June 2006, and the nominal share capital is now DKK 650 million.

As part of the approved buy-back of shares worth DKK 1 billion in 2006, Novozymes purchased treasury shares worth DKK 558 million in the first half of the year. The holding of treasury shares at June 30, 2006 comprised 3.1% of the outstanding shares.

**Outlook for 2006**

The spot rate on August 7, 2006 for the company's key currencies was lower relative to the DKK than the average rates in 2005. Thus the estimated average exchange rate for 2006 is lower for USD and JPY while it is higher for CNY than the average exchange rates for 2005.

(DKK)	USD	JPY	CNY
Average exchange rate 2005	600	5.45	73.25
Spot rate August 7, 2006	581	5.05	72.86
Estimated average exchange rate 2006*	595	5.15	74.30
Change estimated ave. exchange rate 2006 compared with ave. exchange rate 2005	-1%	-5%	1%

\* Estimated ave. exchange rate is calculated as avg. ytd combined with spot rate as of August 7, 2006

**Novozymes confirms its outlook for 2006 for growth in sales and operating profit, while the outlook for free cash flow is being adjusted upwards.**

This outlook is based on exchange rates remaining at their current levels for the rest of 2006, particularly the USD, CNY and JPY. In greater detail, the outlook is as follows:

Sales	Growth in sales of approximately 7-9% in DKK and approximately 6-8% in local currencies.
New products	Total launch of 6-8 new products in 2006.
Operating profit	Growth in operating profit of 7-9%. Operating profit will be negatively affected by less favourable exchange rates than the average exchange rates for 2005, as Novozymes has relatively fewer costs than revenues denominated in foreign currencies. A 5% change in the exchange rate for the USD and JPY is expected to have an impact on operating profit of DKK 30-40 million and DKK 5-15 million respectively.
Operating profit margin	Operating profit margin of approximately 19%.
Net financials	Net financial costs in the region of DKK 100 million.
Net profit	Growth in net profit of 5-7%.
Investments	Investments before acquisitions in the region of DKK 500-600 million.
Free cash flow	Free cash flow before acquisitions in the region of DKK 850-950 million.
ROIC	Return on invested capital (ROIC) of 18-19%.

## Business development update

Novozymes is maintaining its overall strategic frameworks for the business, and a number of new initiatives have also been launched as part of the business development work.

Novozymes invests approximately 12-13% of sales in research and development each year, and the overall research effort is expected to increase in the coming years – partly as a result of the strategic initiative launched in 2005, cf. below, and partly as a result of increased research efforts into enzymes for special areas.

Stock exchange announcement no. 16, 2006

Novozymes A/S  
Investor Relations  
2006-38381-01

Krogshøjvej 36  
2880 Bagsvaerd  
Denmark

Telephone:  
+45 8824 9999  
Telefax:  
+45 4442 1002

Page 8 of 21

Internet:  
[www.novozymes.com](http://www.novozymes.com)  
CVR number:  
10 00 71 27

Increased efforts within enzymes for fuel ethanol

Novozymes intends to increase efforts within enzymes for fuel ethanol in terms of business development, customer service and research and development. The focus on developing new, innovative products for the first-generation technology (starch-based fuel ethanol) will continue, and Novozymes will also undertake a high level of involvement in projects and processes within the second-generation technology (biomass-based fuel ethanol), in order to be able to design the optimal enzymatic solution for the final technology. The increased effort will make enzymes for fuel ethanol one of the Group's two primary commitment areas.

The second-generation technology is currently presenting major challenges and there is still uncertainty as to the process for the final technology. Based on the political positions adopted in the USA and China respectively, it is likely that a second-generation technology will be commercially viable in just over five years; timely enough to replace the first-generation technology when growth begins to diminish in this area.

Updating the long-term growth initiative

In August 2005, based on the company's expectation of continued productivity improvements, it was decided to increase the investment in market-expanding activities by up to DKK 60 million per year over the next 4-5 years. This investment focuses on enzymes and microorganisms, and is targeted at longer-term projects with potential for higher returns and risk than the research portfolio as a whole. Since August 2005 resources have primarily been concentrated on exploring opportunities in selected areas and, to date, the potential has been found to be interesting in a number of these areas, including 'sustainable agriculture and animal husbandry'. Specific development projects have been established within these areas, but are still in the very early stages. Novozymes is confident that several of the areas in question will take shape in research projects in the long term.

As well as additional investments in long-term organic growth, Novozymes is also increasing the focus on possible acquisitions, mainly smaller acquisitions which have a good strategic fit, i.e. are based on the same technology platform, and which can strengthen the company's position within a given area.

Ingredients for the biopharmaceutical industry

Novozymes' strategy in the business area outside enzymes and microorganisms continues to consist in entering into partnerships in the early stages of projects.

Business development within the areas of biopolymers and contract production of pharmaceutical proteins is proceeding to plan and without any substantial changes.

Progress is being made in the project concerning development of antimicrobial peptides for the treatment of antibiotic-resistant bacterial infections. Novozymes has now identified a 'lead candidate', which will be studied further in the preclinical trials now under way; these are expected to be completed during 2007.

Stock exchange announcement no. 16, 2006

Novozymes A/S  
Investor Relations  
2006-38381-01

Krogshøjvej 36  
2880 Bagsvaerd  
Denmark

Telephone:  
+45 8824 9999  
Telefax:  
+45 4442 1002

Page 9 of 21

Internet:  
[www.novozymes.com](http://www.novozymes.com)  
CVR number:  
10 00 71 27

The latest initiative in the area 'ingredients for the biopharmaceutical industry' is recombinant proteins as a medium for cell cultures. The project concerning development of recombinant human serum albumin (rHSA) as a medium for cell cultures has shown progress, and satisfactory results have been obtained for a product at laboratory scale. An agreement has just been entered into with US-based Celliance Corporation, a subsidiary of Serologicals Corporation, to look into the commercialisation opportunities for rHSA. Test marketing is expected to be carried out with a number of potential customers in the second half of 2006.

In June 2006 Novozymes also bought the UK company Delta Biotechnology Ltd (now Novozymes Delta Ltd) from the Sanofi-Aventis Group. Novozymes Delta Ltd has a number of interesting development projects in the pipeline, including recombinant transferrin, which is another of the key proteins in media for cell cultures, and which complements Novozymes' own research project concerning development of rHSA. The company's leading product, Recombumin<sup>®</sup>, is the first commercially available recombinant human serum albumin approved by the FDA (the American Health Authorities). The acquisition of Novozymes Delta Ltd has given Novozymes access to significant know-how and technology within this area.

## Environmental and social discussion

### Appendix 5

#### **Water and energy – effective utilisation of resources**

Consumption of water and energy, adjusted for stockbuilding in the period, rose by 1% and 2% respectively in the first half of 2006 compared with the first half of 2005. The relative increase in the consumption of both water and energy, compared with 2005, is expected to rise in the second half, albeit still within the target of a maximum increase in actual consumption of water and energy of 7% and 9% respectively.

#### **Significant spills**

There were no significant spills in the first half of 2006.

#### **Occupational accidents**

The frequency of reported occupational accidents resulting in absence fell in the first half of 2006 to 3.0 per million working hours, compared with 5.3 in the same period of 2005.

#### **Rate of employee turnover and absence**

Calculated at the end of the first half of 2006, the rate of employee turnover for the 12 months to date was 7.4%, equivalent to an increase of 1.7 percentage points on the corresponding period of last year. The rate of absence was 2.5% for the period, which is 0.4 percentage points lower than the first half of 2005.



Novozymes has set a number of targets within the environmental and social area for 2006. A complete overview of these targets will be found in The Novozymes Report 2005, see [www.novozymes.com](http://www.novozymes.com).

## Forward-looking statements

This stock exchange announcement contains forward-looking statements, including the financial outlook for 2006. Forward-looking statements are, by their very nature, associated with risks and uncertainties that may cause actual results to differ materially from expectations. The uncertainties may include unexpected developments in the international currency exchange and securities markets, market-driven price decreases for Novozymes' products, and the introduction of competing products within Novozymes' core areas.

**Bagsværd, August 8, 2006**

**Board of Directors  
Novozymes A/S**

**Stock exchange announcement no. 16, 2006**

Novozymes A/S  
Investor Relations  
2006-38381-01

Krogshøjvej 36  
2880 Bagsværd  
Denmark

Telephone:  
+45 8824 9999  
Telefax:  
+45 4442 1002

**Page 11 of 21**

Internet:  
[www.novozymes.com](http://www.novozymes.com)  
CVR number:  
10 00 71 27

## Contact persons

### Media relations:

Eva Veileborg Hald

Tel. (direct): +45 4442 3338

Tel. (mobile): +45 3079 3338

Cirkeline Buron

Tel. (direct): +45 4446 0626

Tel. (mobile): +45 3077 0626

### Investor relations:

Lene Aaboe

Tel. (direct): +45 4446 0082

Tel. (mobile): +45 3077 0082

Tobias Bjørklund

Tel. (direct): +45 4442 8682

Tel. (mobile): +45 3079 8682

Ian Christensen

Tel. (direct): +45 4446 0341

Tel. (mobile): +45 3077 0341

*Novozymes is the biotech-based world leader in enzymes and microorganisms. Using nature's own technologies, we continuously expand the frontiers of biological solutions to improve industrial performance everywhere. Headquartered in Denmark, Novozymes employs more than 4,000 people in more than 30 countries. Novozymes produces and sells more than 600 products in 130 countries. Novozymes A/S' B shares are listed on the Copenhagen Stock Exchange. For further company information, visit Novozymes on the Internet at [www.novozymes.com](http://www.novozymes.com).*

Stock exchange announcement no. 16, 2006

Novozymes A/S  
Investor Relations  
2006-38381-01

Krogshøjvej 36  
2880 Bagsvaerd  
Denmark

Telephone:  
+45 8824 9999  
Telefax:  
+45 4442 1002

Page 12 of 21  
Internet:  
[www.novozymes.com](http://www.novozymes.com)  
CVR number:  
10 00 71 27

# Statement of the Board of Directors and the Management

The Board of Directors and the Management have considered and approved the unaudited Group financial statement for Novozymes A/S for the second quarter of 2006.

The financial statement has been prepared in accordance with International Financial Reporting Standards (IFRS), as adopted by the EU, and the regulations of the Copenhagen Stock Exchange for the presentation of quarterly financial statements by listed companies.

In our opinion the accounting policies used are appropriate and the Group financial statement gives a true and fair view of the Group's assets, liabilities, net profit and financial position at June 30, 2006, and of the Group's activities and cash flow for the second quarter of 2006.

Bagsværd, August 8, 2006

## Management:

Steen Riisgaard  
*President and CEO*

Per Falholt

Per Månsson

Peder Holk Nielsen

Arne W. Schmidt

## Board of Directors:

Henrik Gürtler  
*Chairman*

Kurt Anker Nielsen  
*Vice Chairman*

Paul Petter Aas

Jerker Hartwall

Arne Hansen

Søren Jepsen

Ulla Morin

Walther Thygesen

Hans Werdelin

Stock exchange announcement no. 16, 2006

Novozymes A/S  
Investor Relations  
2006-38381-01

Krogshøjvej 36  
2880 Bagsværd  
Denmark

Telephone:  
+45 8824 9999  
Telefax:  
+45 4442 1002

Page 13 of 21

Internet:  
[www.novozymes.com](http://www.novozymes.com)  
CVR number:  
10 00 71 27

# Appendices

Appendix 1	Main items and key figures
Appendix 2	Distribution of sales
	2.1 By industry
	2.2 By geographical area
	2.3 Quarterly sales by industry
	2.4 Quarterly sales by geographical area
Appendix 3	Statement of cash flow and financial resources
Appendix 4	Balance sheet and Statement of shareholders' equity
	4.1 Balance sheet
	4.2 Statement of shareholders' equity
Appendix 5	Selected key figures, environmental and social area
Appendix 6	Overview of Stock exchange announcements for 2006 to date (excluding insider trading)
Appendix 7	Financial calendar 2006

## Appendix 1: Main items and key figures

(DKK million)	2006 1H	2005 1H	%change 1H/1H	2006 Q2	2005 Q2	% change 2Q/2Q
<b>Sales</b>	<b>3,282</b>	<b>3,037</b>	<b>8%</b>	<b>1,649</b>	<b>1,561</b>	<b>6%</b>
- Enzymes	3,098	2,881	8%	1,559	1,479	5%
- Microorganisms	184	156	18%	90	82	10%
<b>Gross profit</b>	<b>1,795</b>	<b>1,641</b>	<b>9%</b>	<b>913</b>	<b>858</b>	<b>6%</b>
Gross margin	54.7%	54.0%	-	55.4%	55.0%	-
<b>Operating profit</b>	<b>657</b>	<b>597</b>	<b>10%</b>	<b>344</b>	<b>322</b>	<b>7%</b>
Operating profit margin	20.0%	19.7%	-	20.9%	20.6%	-
<b>Net financials</b>	<b>(66)</b>	<b>(8)</b>	<b>-</b>	<b>(18)</b>	<b>0</b>	<b>-</b>
Profit before tax	591	589	0%	326	322	1%
Corporation tax	(148)	(148)	0%	(79)	(74)	7%
Net profit	443	441	0%	247	248	0%
Attributable to:						
S shareholders in the parent company	438	440	0%	244	248	-2%
Equity minority interests	5	1	-	3	0	-
Foreign exchange gain/(loss), net	(51)	9	-	(27)	5	-
Interest income/(costs)	(3)	(12)	-	7	(4)	-
Other financial items	(12)	(5)	-	2	(1)	-
Total financial income/(costs)	(66)	(8)	-	(18)	0	-
<b>Earnings per DKK 10 share</b>	<b>6.89</b>	<b>6.65</b>	<b>4%</b>	<b>3.83</b>	<b>3.74</b>	<b>2%</b>
Average no. of A/B shares, outstanding (million)	63.5	66.2	-	63.7	66.3	-
<b>Earnings per DKK 10 share (diluted)</b>	<b>6.72</b>	<b>6.49</b>	<b>4%</b>	<b>3.73</b>	<b>3.67</b>	<b>2%</b>
Weighted ave. no. of outstanding shares, diluted (million)	65.2	67.8	-	65.4	67.6	-
<b>Free cash flow before acquisitions</b>	<b>600</b>	<b>480</b>	<b>25%</b>	<b>308</b>	<b>213</b>	<b>45%</b>
Return on invested capital after tax (ROIC), incl. goodwill	19.7%	19.6%	-	20.7%	21.9%	-
<b>Net interest-bearing debt</b>	<b>1,030</b>	<b>788</b>	<b>31%</b>	<b>1,030</b>	<b>788</b>	<b>31%</b>
Equity ratio	47.6%	53.1%	-	47.6%	53.1%	-
Return on equity	24.3%	22.5%	-	28.1%	25.9%	-

Stock exchange announcement no. 16, 2006

Novozymes A/S  
Investor Relations  
2006-38381-01

Krogshoejvej 36  
2880 Bagsvaerd  
Denmark

Telephone:  
+45 8824 9999  
Telefax:  
+45 4442 1002

Page 15 of 21

Internet:  
www.novozymes.com  
CVR number:  
10 00 71 27

## Appendix 2: Distribution of sales

### 2.1 By industry

(DKK million)	2006 1H	2005 1H	% change YTD	2006 Q2	2005 Q2	% change Q2 / Q2
<b>Enzymes</b>	<b>3,098</b>	<b>2,881</b>	<b>8</b>	<b>1,559</b>	<b>1,479</b>	<b>5</b>
- technical enzymes	1,963	1,789	10	982	915	7
- detergent	997	990	1	492	490	0
- other technical	966	799	21	490	425	15
- food enzymes	791	752	5	404	396	2
- feed enzymes	344	340	1	173	168	3
<b>Microorganisms</b>	<b>184</b>	<b>156</b>	<b>18</b>	<b>90</b>	<b>82</b>	<b>10</b>
<b>Sales</b>	<b>3,282</b>	<b>3,037</b>	<b>8</b>	<b>1,649</b>	<b>1,561</b>	<b>6</b>

### 2.2 By geographical area

(DKK million)	2006 1H	2005 1H	% change YTD	% currency impact	% change in local currency
Europe, Middle East & Africa	1,372	1,380	(1)	(0)	(1)
North America	1,012	854	19	(6)	13
Asia Pacific	681	601	13	(4)	9
Latin America	217	202	7	(5)	2
<b>Sales</b>	<b>3,282</b>	<b>3,037</b>	<b>8</b>	<b>(3)</b>	<b>5</b>

### 2.3 Quarterly sales by industry

(DKK million)	2006			2005			% change
	Q2	Q1	Q4	Q3	Q2	Q1	Q2 / Q2
<b>Enzymes</b>	<b>1,559</b>	<b>1,539</b>	<b>1,549</b>	<b>1,543</b>	<b>1,479</b>	<b>1,402</b>	<b>5</b>
- technical enzymes	982	981	987	958	915	874	7
- detergent	492	505	508	516	490	500	0
- other technical	490	476	479	442	425	374	15
- food enzymes	404	387	354	385	396	356	2
- feed enzymes	173	171	208	200	168	172	3
<b>Microorganisms</b>	<b>90</b>	<b>94</b>	<b>75</b>	<b>77</b>	<b>82</b>	<b>74</b>	<b>10</b>
<b>Sales</b>	<b>1,649</b>	<b>1,633</b>	<b>1,624</b>	<b>1,620</b>	<b>1,561</b>	<b>1,476</b>	<b>6</b>

### 2.4 Quarterly sales by geographical area

(DKK million)	2006			2005			% change
	Q2	Q1	Q4	Q3	Q2	Q1	Q2 / Q2
Europe, Middle East & Africa	689	683	656	723	714	666	(4)
North America	507	505	475	444	440	414	15
Asia Pacific	340	341	351	326	303	298	12
Latin America	113	104	142	127	104	98	9
<b>Sales</b>	<b>1,649</b>	<b>1,633</b>	<b>1,624</b>	<b>1,620</b>	<b>1,561</b>	<b>1,476</b>	<b>6</b>

Stock exchange announcement no. 16, 2006

Novozymes A/S  
Investor Relations  
2006-38381-01

Krogshoejvej 36  
2880 Bagsvaerd  
Denmark

Telephone:  
+45 8824 9999  
Telefax:  
+45 4442 1002

Page 16 of 21

Internet:  
www.novozymes.com  
CVR number:  
10 00 71 27

## Appendix 3: Statement of cash flow

(DKK million)	2006 1H	2005 1H
<b>Net profit</b>	<b>443</b>	<b>441</b>
Reversals of non-cash expenses	501	296
Corporation tax paid	44	(176)
Interest received	64	25
Interest paid	(85)	(29)
<b>Cash flow before change in working capital</b>	<b>967</b>	<b>557</b>
<b>Change in working capital</b>		
(Increase)/decrease in receivables	(95)	75
(Increase)/decrease in inventories	(71)	(118)
Other liabilities	(17)	91
<b>Cash flow from operating activities</b>	<b>784</b>	<b>605</b>
<b>Investments</b>		
Purchase of intangible fixed assets	(12)	(4)
Sale of property, plant & equipment	18	7
Purchase of property, plant & equipment	(190)	(128)
<b>Cash flow from investing activities before acquisitions</b>	<b>(184)</b>	<b>(125)</b>
<b>Free cash flow before acquisitions</b>	<b>600</b>	<b>480</b>
Acquisition of activities and companies	(66)	-
<b>Free cash flow after acquisitions</b>	<b>534</b>	<b>480</b>

## Appendix 4: Balance sheet and Statement of shareholders' equity

### 4.1: Balance sheet, June 30, 2006

Assets (DKK million)	2006 1H	2005 End
Completed IT development projects	41	52
Acquired patents, licences and know-how	258	239
Goodwill	130	120
IT development projects in progress	23	20
<b>Intangible fixed assets</b>	<b>452</b>	<b>431</b>
Land and buildings	1,730	1,796
Production equipment and machinery	926	985
Other equipment	302	315
Plant, property and equipment under construction	454	381
<b>Property, plant and equipment</b>	<b>3,412</b>	<b>3,477</b>
<b>Deferred tax assets</b>	<b>33</b>	<b>42</b>
<b>Non-current financial assets (non interest-bearing)</b>	<b>25</b>	<b>20</b>
<b>Total fixed assets</b>	<b>3,922</b>	<b>3,970</b>
Raw materials and consumables	174	178
Goods in progress	289	305
Finished goods	787	714
<b>Inventories</b>	<b>1,250</b>	<b>1,197</b>
Trade receivables	1,063	1,056
Tax receivable	162	318
Other receivables	178	163
<b>Receivables</b>	<b>1,403</b>	<b>1,537</b>
Financial assets (interest-bearing)	126	132
Financial assets (non interest-bearing)	64	19
<b>Total financial assets</b>	<b>190</b>	<b>151</b>
<b>Cash at bank and in hand</b>	<b>600</b>	<b>454</b>
<b>Total current assets</b>	<b>3,443</b>	<b>3,339</b>
<b>Total assets</b>	<b>7,365</b>	<b>7,309</b>

Stock exchange announcement no. 16, 2006

Novozymes A/S  
Investor Relations  
2006-38381-01

Krogshoejvej 36  
2880 Bagsvaerd  
Denmark

Telephone:  
+45 8824 9999  
Telefax:  
+45 4442 1002

Page 18 of 21

Internet:  
www.novozymes.com  
CVR number:  
10 00 71 27

<b>Liabilities and shareholders' equity</b> <b>(DKK million)</b>	<b>2006</b> <b>1H</b>	<b>2005</b> <b>End</b>
Share capital	650	696
Treasury shares	(923)	(1,659)
Other reserves	114	122
Retained earnings	3,630	4,602
Minority interests	38	33
<b>Total shareholders' equity</b>	<b>3,509</b>	<b>3,794</b>
Deferred tax liabilities	557	574
Long-term employee benefits	12	17
Non-current provisions	88	63
Non-current financial liabilities (interest-bearing)	1,676	1,353
Non-current financial liabilities (non interest-bearing)	48	43
Other non-current liabilities (interest-bearing)	23	23
<b>Total non-current liabilities</b>	<b>2,404</b>	<b>2,073</b>
Financial liabilities (interest-bearing)	57	87
Financial liabilities (non interest-bearing)	16	81
Provisions	20	11
Trade payables	243	259
Amount owed to related parties	48	54
Tax payable	78	48
Other current liabilities	990	902
<b>Total current liabilities</b>	<b>1,452</b>	<b>1,442</b>
<b>Total liabilities</b>	<b>3,856</b>	<b>3,515</b>
<b>Total liabilities and shareholders' equity</b>	<b>7,365</b>	<b>7,309</b>

## 4.2 Statement of shareholders' equity, 1st half 2006

(DKK million)	2006	2005
	1H	End
<b>Shareholders' equity excl. minority interests - beginning of period</b>	<b>3,761</b>	<b>3,917</b>
Net profit	443	858
Dividend paid	(255)	(231)
Purchase of treasury shares, net	(468)	(927)
Fair value and currency adjustments, etc.	(10)	144
<b>Shareholders' equity excl. minority interests</b>	<b>3,471</b>	<b>3,761</b>
Minority interests - Beginning of period	33	30
Net profit	5	3
Dividend paid	(2)	(1)
Currency adjustments, etc.	(2)	1
Change in minority interests	4	0
<b>Minority interests - end of period</b>	<b>38</b>	<b>33</b>
<b>Total equity - end of period</b>	<b>3,509</b>	<b>3,794</b>